The MoA of cibisatamab is based on the simultaneous binding of cibisatamab to CEA/CEACAM5 on tumor cells and to the CD3ε chain on T cells, which results in T-cell activation and subsequent tumor cell killing (7, 8). This evidence concerns the gene CEACAM5 and neoplasm.